744 related articles for article (PubMed ID: 31147872)
1. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.
Sattiraju A; Mintz A
Adv Exp Med Biol; 2019; 1147():65-91. PubMed ID: 31147872
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma Stem Cells and Their Microenvironment.
Sattiraju A; Sai KKS; Mintz A
Adv Exp Med Biol; 2017; 1041():119-140. PubMed ID: 29204831
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes.
Caspani EM; Crossley PH; Redondo-Garcia C; Martinez S
PLoS One; 2014; 9(7):e101402. PubMed ID: 25032689
[TBL] [Abstract][Full Text] [Related]
4. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
Li M; Li G; Kiyokawa J; Tirmizi Z; Richardson LG; Ning J; Das S; Martuza RL; Stemmer-Rachamimov A; Rabkin SD; Wakimoto H
Acta Neuropathol Commun; 2020 Dec; 8(1):221. PubMed ID: 33308315
[TBL] [Abstract][Full Text] [Related]
5. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.
Persano L; Rampazzo E; Basso G; Viola G
Biochem Pharmacol; 2013 Mar; 85(5):612-622. PubMed ID: 23063412
[TBL] [Abstract][Full Text] [Related]
7. Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration.
Uneda A; Kurozumi K; Fujimura A; Fujii K; Ishida J; Shimazu Y; Otani Y; Tomita Y; Hattori Y; Matsumoto Y; Tsuboi N; Makino K; Hirano S; Kamiya A; Date I
Acta Neuropathol Commun; 2021 Feb; 9(1):29. PubMed ID: 33618763
[TBL] [Abstract][Full Text] [Related]
8. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
9. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
Arbab AS; Rashid MH; Angara K; Borin TF; Lin PC; Jain M; Achyut BR
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258180
[TBL] [Abstract][Full Text] [Related]
10. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.
Shao R; Taylor SL; Oh DS; Schwartz LM
Oncotarget; 2015 Dec; 6(38):40507-18. PubMed ID: 26439689
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
[No Abstract] [Full Text] [Related]
12. Glioblastoma precision therapy: From the bench to the clinic.
Zhou Y; Wu W; Bi H; Yang D; Zhang C
Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
14. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies.
Fanelli GN; Grassini D; Ortenzi V; Pasqualetti F; Montemurro N; Perrini P; Naccarato AG; Scatena C
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804731
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma multiforme: novel therapeutic targets.
Muir M; Gopakumar S; Traylor J; Lee S; Rao G
Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
[TBL] [Abstract][Full Text] [Related]
16. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
17. [The stem cell niche in glioblastoma: from fundamental aspects to targeted therapies].
Turpin A; Sharif A; Stoven L; Blond S; Maurage CA; Le Rhun É
Bull Cancer; 2015 Jan; 102(1):24-33. PubMed ID: 25609493
[TBL] [Abstract][Full Text] [Related]
18. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
[TBL] [Abstract][Full Text] [Related]
19. Upregulated functional gene expression programmes in tumour pericytes mark progression in patients with low-grade glioma.
Oudenaarden C; Sjölund J; Pietras K
Mol Oncol; 2022 Jan; 16(2):405-421. PubMed ID: 34018679
[TBL] [Abstract][Full Text] [Related]
20. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
Nigim F; Cavanaugh J; Patel AP; Curry WT; Esaki S; Kasper EM; Chi AS; Louis DN; Martuza RL; Rabkin SD; Wakimoto H
J Neuropathol Exp Neurol; 2015 Jul; 74(7):710-22. PubMed ID: 26083570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
